C-8M5WGlyscend
gut-targeted polymers, dynamic barrier, metabolic surgery mimicry
modulatingdevice hardware
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-8M5W
C-8M5WC-8M5Wgut-targeted polymers, dynamic barrier, metabolic surgery mimicry
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Glyscend states that type 2 diabetes can be treated more effectively by translating the clinical insight behind bariatric surgery into a non-invasive therapy that fits the traditional care pathway. The company presents itself as dedicated to revolutionizing treatment by helping patients control glucose while avoiding side effects such as weight gain and hypoglycemia, with the broader aim of improving control for millions of people.
SourceGlyscend states that type 2 diabetes treatment can be transformed by using a non-invasive therapy modeled on the mechanism behind bariatric surgery's immediate remission effects, while preserving the traditional care pathway. The company says it is dedicated to helping patients control glucose effectively and avoid side effects such as weight gain and hypoglycemia, with the broader aim of changing treatment for millions of people.
SourceGlyscend states that type 2 diabetes can be treated through a truly revolutionary yet non-invasive approach inspired by the immediate disease remission seen after bariatric surgery. The company believes this mechanism can be reproduced without surgery while preserving the traditional care pathway, giving patients effective glucose control and avoiding side effects such as weight gain and hypoglycemia.
SourceGlyscend states that type 2 diabetes should be treated, not merely managed, through a non-invasive therapy inspired by the immediate diabetes remission seen after bariatric surgery. The company believes an orally ingestible intestinal coating can act on the same mechanism as surgery within the traditional care pathway, helping patients control glucose without side effects such as weight gain and hypoglycemia while giving physicians better tools to address the disease itself.
SourceGlyscend states a belief that type 2 diabetes treatment should be rethought, framing the disease as one marked by uncontrolled progression and suggesting that a new approach is needed for an old disease. The visible text presents the company as mission-driven around addressing an unmet need in how type 2 diabetes is treated.
Source